Gain Therapeutics reports stable motor scores after 12 months in rexaceract Phase 1b study
GANX•
GANX•Gain Therapeutics reported stable motor scores without overall disease progression among 13 evaluable participants who completed 12 months of daily rexaceract treatment for Parkinson’s disease. The company said the treatment was generally well tolerated, with no new safety concerns during a nine-month extension.
Gain Therapeutics presented Phase 1b results for rexaceract in Parkinson’s disease at the 31st IAPRD World Congress. Motor scores remained stable without overall disease progression among 13 evaluable participants completing 12 months of daily oral treatment; the company reported no new safety concerns during the nine-month extension.
Additional biomarker findings are expected by year-end 2026. Presented preclinical results showed GT-04686 improved motor and nonmotor function, and selection of an initial therapeutic indication is expected by the end of the fourth quarter of 2026.